U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06814730) titled 'A Study to Assess THN391 in Subjects with Alzheimer's Disease' on Dec. 24, 2024.
Brief Summary: This is a Phase 1b study to evaluate different doses of the drug and see whether a drug is safe and how it behaves in the body.
THN391 has already been assessed in healthy people without Alzheimer's disease. This is the first study of THN391 in patients with Early Alzheimer's disease. Later studies will evaluate THN391 to see if it is effective for the treatment of Alzheimer's disease.
In this study, THN391 will be compared with a placebo (a look-alike substance that contains no drug). The study duration is approximately 6 months in whic...